Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham, Birmingham, B18 7QH, England, UK.
Curr Hypertens Rep. 2012 Jun;14(3):183-92. doi: 10.1007/s11906-012-0263-x.
The possibility of carcinogenic side effects of antihypertensive therapies due to their chronic administration has been raised multiple times in the past. Recently, the issue has again drawn attention, this time in relation to angiotensin receptor blockers (ARBs). This, among others, caused both American and European drug regulation authorities to review the underlying evidence concerning the relationship between this class of medications and potential adverse carcinogenic outcome. A plethora of both basic science and preclinical evidence has been generated, and three meta-analyses and one nationwide cohort have focused on this specific question. The current review aims to summarize the contemporary multidisciplinary evidence on whether ARBs may be associated with an increased risk of tumorigenesis.
过去曾多次提出，由于长期服用，降压治疗可能会产生致癌的副作用。最近，这个问题再次引起了关注，这次是与血管紧张素受体阻滞剂（ARBs）有关。这促使美国和欧洲的药品监管机构审查了有关此类药物与潜在致癌不良后果之间关系的基础证据。已经产生了大量的基础科学和临床前证据，三项荟萃分析和一项全国性队列研究都集中在这个具体问题上。本综述旨在总结当前关于 ARB 是否可能与肿瘤形成风险增加相关的多学科证据。
